公开(公告)号：WO1997006827A1

公开(公告)日：1997-02-27

申请号：PCT/US1996012598

申请日：1996-07-31

Applicant: ICN PHARMACEUTICALS

Inventor： ICN PHARMACEUTICALS ,  PIETRZKOW, Zbigniew ,  DARIUSZ, Cieslak ,  RUZDIJIC, Sabera

IPC: A61K48/00

CPC classification number: C12N15/1138 ,  A61K38/00

Abstract: Neoplastic cells which over-express CD44, including especially non-small cell lung cancer and melanoma cancer cells, are treated with antisense oligonucleotides to control CD44 expression. Test results show that the claimed oligonucleotides significantly decreases cell growth in a CD44 sequence specific manner of lung cancer or melanoma cells, or both, but are largely non-toxic to normal cells. Examples of dosing in a clinical setting are provided.

Abstract translation: 过表达CD44的肿瘤细胞，特别是非小细胞肺癌和黑素瘤癌细胞，用反义寡核苷酸处理以控制CD44表达。 测试结果表明，所要求保护的寡核苷酸显着降低肺癌或黑素瘤细胞或两者的CD44序列特异性方式的细胞生长，但对正常细胞大部分无毒性。 提供临床设置中的给药实例。

公开(公告)号：WO1996036274A1

公开(公告)日：1996-11-21

申请号：PCT/US1996006805

申请日：1996-05-14

Applicant: ICN PHARMACEUTICALS

Inventor： ICN PHARMACEUTICALS ,  ZEYTINOGLU, Fusun ,  THIEBAUT, Franz, B.

IPC: A61B05/00

CPC classification number: G01N33/569 ,  A61B10/0035 ,  G01N33/53 ,  G01N33/54366 ,  G01N2333/025 ,  G01N2333/035 ,  G01N2333/15 ,  G01N2333/16 ,  G01N2333/20 ,  G01N2333/33 ,  G01N2333/35 ,  G01N2333/38 ,  G01N2333/40 ,  Y02A50/54 ,  Y10S436/805

Abstract: An antibody targeted to an antigen is brought into contact with a body component in situ. The resulting antibody/antigen complex is labeled and may be amplified. The label is then detected either in situ or ex situ.

Abstract translation: 使靶向抗原的抗体与原位成分接触。 所得的抗体/抗原复合物被标记并可以扩增。 然后在原位或非原位检测标记。

公开(公告)号：WO1998016186A2

公开(公告)日：1998-04-23

申请号：PCT/US1997018767

申请日：1997-10-15

Applicant: ICN PHARMACEUTICALS ,  RAMASAMY, Kandasamy ,  TAM, Robert ,  AVERETT, Devron

Inventor： ICN PHARMACEUTICALS

IPC: A61K00/00

CPC classification number: C07H19/04

Abstract: Novel monocyclic L-nucleoside compounds have general formula (I). Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.

Abstract translation: 新型单环L-核苷化合物具有通式（I）。 这些化合物的实施方案被认为可用于治疗多种疾病，包括感染，感染，肿瘤和自身免疫性疾病。 从机理来看，新化合物的实施方案显示免疫调节活性，并且预期可用于调节细胞因子模式，包括Th1和Th2应答的调节。

公开(公告)号：WO1996014329A1

公开(公告)日：1996-05-17

申请号：PCT/US1995014600

申请日：1995-11-02

Applicant: ICN PHARMACEUTICALS ,  WANG, Guangyi ,  RAMASAMY, Kandasamy ,  SEIFERT, Wilfried

Inventor： ICN PHARMACEUTICALS

IPC: C07H19/06

CPC classification number: C07H19/06 ,  C07H19/10 ,  C07H21/00

Abstract: A number of modified nucleosides are disclosed composed of modified sugar moieties which contain substituents at C1 and C4 positions, or branched substituents at C3 and C5 positions of deoxyribose or ribose. Each nucleoside is converted to or properly protected and them converted to the corresponding phosphoramidites. These phosphoramidites are used to assemble oligonucleotides in which there is at least one of the forenoted nucleosides. These sugar modified oligonucleotides have the potential to be used as antisense therapies since they are expected to enhance nuclease resistance and cellular uptake while they maintain sequence-specificity and affinity to nucleic acid targets in vitro or in vivo.

Abstract translation: 公开了一些修饰的核苷，其由在C1和C4位置含有取代基的修饰的糖部分或脱氧核糖或核糖的C3和C5位置的支链取代基组成。 将每个核苷转化为或适当保护，并将其转化为相应的亚磷酰胺。 这些亚磷酰胺用于组装寡核苷酸，其中存在至少一种预先注入的核苷。 这些糖修饰的寡核苷酸具有用作反义治疗的潜力，因为预期它们在体外或体内保持对核酸靶标的序列特异性和亲和力，从而增强核酸酶抗性和细胞摄取。

公开(公告)号：WO1997026883A1

公开(公告)日：1997-07-31

申请号：PCT/US1997000600

申请日：1997-01-21

Applicant: ICN PHARMACEUTICALS ,  TAM, Robert ,  RAMASAMY, Kandsamy ,  AVERETT, Devron

Inventor： ICN PHARMACEUTICALS

IPC: A61K31/52

CPC classification number: C07H19/16 ,  A61K31/7056 ,  A61K38/21 ,  A61K45/06 ,  C07H19/052 ,  C07H19/056 ,  C07H19/24 ,  A61K2300/00

Abstract: Ribavirin3 is administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. In particular, Ribavirin3 is used to suppress Th2-mediated T cell responses and promote Th1-mediated T cell response. In other aspects of the invention, one or more Ribavirin3 analogs are administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. The Ribavirin3 analog(s) may be used to suppress or enhance Th1 or Th2-mediated T cell responses.

Abstract translation: 利巴韦林3以有效调节活化T细胞淋巴因子表达的剂量范围给予患者。 特别是，利巴韦林3用于抑制Th2介导的T细胞应答并促进Th1介导的T细胞应答。 在本发明的其它方面，一种或多种利巴韦林3类似物以有效调节活化的T细胞中淋巴因子表达的剂量范围给予患者。 利巴韦林3类似物可用于抑制或增强Th1或Th2介导的T细胞应答。

公开(公告)号：WO1997019097A1

公开(公告)日：1997-05-29

申请号：PCT/US1996018406

申请日：1996-11-16

Applicant: ICN PHARMACEUTICALS

Inventor： ICN PHARMACEUTICALS ,  PIETRZKOWSKI, Zbigniew ,  CIESLAK, Dariusz ,  OLBINA, Gordana

IPC: C07H21/04

CPC classification number: C12N15/1136 ,  A61K38/00 ,  C12N15/1138

Abstract: Oligonucleotides are provided which are effective in inhibiting the growth, metastasis and/or angiogenesis of tumors, including particularly melanoma and/or lung cancer. Methods are also provided for use of these olignonucleotides in the treatment of diseases.

Abstract translation: 提供寡核苷酸，其有效抑制肿瘤的生长，转移和/或血管生成，包括特别是黑素瘤和/或肺癌。 还提供了使用这些寡核苷酸治疗疾病的方法。

公开(公告)号：WO1997004312A1

公开(公告)日：1997-02-06

申请号：PCT/US1996010090

申请日：1996-06-10

Applicant: ICN PHARMACEUTICALS

Inventor： ICN PHARMACEUTICALS ,  DEFTOS, Leonard, J. ,  WITTY, Thomas, R.

IPC: G01N33/53

CPC classification number: C07K14/635 ,  A61K38/00 ,  C07K16/26

Abstract: The invention provides antibodies and other epitope-specific binding molecules capable of specifically binding to an epitope or epitopes on parathyroid hormone-related protein (PTHRP) 140-173 and/or PTHRP 109-141. Other aspects of the invention involve providing various polypeptides and other molecules capable of binding to the epitope-specific binding molecules of the invention, and assays and kits for the detection of PTHRP in tissues, cells and/or fluids, and the diagnosis, monitoring and/or treatment of various diseases.

Abstract translation: 本发明提供能够特异性结合甲状旁腺激素相关蛋白（PTHRP）140-173和/或PTHRP 109-141上的表位或表位的抗体和其他表位特异性结合分子。 本发明的其它方面涉及提供能够结合本发明的表位特异性结合分子的各种多肽和其它分子，以及用于在组织，细胞和/或流体中检测PTHRP的测定和试剂盒，以及诊断，监测和 /或治疗各种疾病。

公开(公告)号：WO1998016184A2

公开(公告)日：1998-04-23

申请号：PCT/US1997018387

申请日：1997-10-15

Applicant: ICN PHARMACEUTICALS ,  WANG, Guangyi ,  TAM, Robert ,  AVERTT, Deveron

Inventor： ICN PHARMACEUTICALS

IPC: A61K00/00

CPC classification number: C07H19/16 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/70 ,  A61K31/7056 ,  A61K31/7076 ,  A61K31/7115 ,  A61K45/06 ,  C07H19/04

Abstract: Novel purine L-nucleoside compounds are disclosed, in which both the purine rings and the sugar are either modified, functionalized or both. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, and infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Th1 and Th2.

Abstract translation: 公开了新型嘌呤L-核苷化合物，其中嘌呤环和糖都被修饰，官能化或两者都是。 新化合物或其药学上可接受的酯或其盐可以用于药物组合物中，并且这种组合物可用于治疗感染，感染肿瘤或自身免疫性疾病。 新化合物也可用于调节免疫系统的方面，包括Th1和Th2的调节。

公开(公告)号：WO1998008737A2

公开(公告)日：1998-03-05

申请号：PCT/US1997014921

申请日：1997-08-25

Applicant: ICN PHARMACEUTICALS

Inventor： ICN PHARMACEUTICALS ,  SANDOR, Joseph

IPC: B65B00/00

CPC classification number: G21F5/00 ,  G21F5/06

Abstract: A packaging system for the transportation and storage of materials, including radioactive and other hazardous materials. The container comprises a primary container removably received within a secondary container, and the secondary container being removably received within a tertiary container. In preferred embodiments the primary container can be centrifuged to minimize unrecoverable material, and in especially preferred embodiments involving radioactive materials, the primary container is the only component that must be considered as radioactive waste.

Abstract translation: 用于运输和储存材料的包装系统，包括放射性和其他有害物质。 容器包括可移除地容纳在次级容器内的主容器，并且次级容器可移除地容纳在第三容器内。 在优选的实施方案中，主容器可被离心以最小化不可回收的材料，并且在涉及放射性物质的特别优选的实施方案中，主容器是必须被视为放射性废物的唯一部件。

公开(公告)号：WO1997038666A2

公开(公告)日：1997-10-23

申请号：PCT/US1997006720

申请日：1997-04-07

Applicant: ICN PHARMACEUTICALS

Inventor： ICN PHARMACEUTICALS ,  FUSUN, Zeytinoglu

IPC: A61K00/00

CPC classification number: C12N7/00 ,  C12N2770/24211 ,  C12N2770/24251

Abstract: The gasification portion of an IGCC plant has a desulphurization which desulphurizes a sulphur containing fluid to produce a clean gas, the clean gas is power producingly expanded in an expander to provide refrigeration to the desulpherization unit, and there is at least one intervening process unit other than a heat exchanger with the sulphur containing fluid, which is functionally positioned between the desulphurization unit and the expander. Preferred embodiments include systems in which the intervening process unit comprises a membrane separator, synthesis unit or other device involved in coproduction, or a heat exchanger with cold nitrogen expanded downstream of an elevated pressure air separation unit.

Abstract translation: IGCC设备的气化部分具有脱硫，其将含硫流体脱硫以产生清洁气体，清洁气体在膨胀机中产生功率产生膨胀以向脱灰装置提供制冷，并且至少有一个中间处理单元其它 比具有含硫流体的热交换器功能上位于脱硫单元和膨胀机之间。 优选实施方案包括其中中间处理单元包括膜分离器，合成单元或涉及共同生产的其它装置的系统，或者在高压空气分离单元的下游膨胀的具有冷氮的热交换器。